Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385871683> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4385871683 endingPage "3972" @default.
- W4385871683 startingPage "3965" @default.
- W4385871683 abstract "PURPOSE The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal cancers. MATERIALS AND METHODS Radiotherapy was administered in both arms: 1.8- to 2.0-Gy/d fractions Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy. The investigational arm received chemotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 during radiotherapy; postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for three courses. Patients were stratified by tumor stage, nodal stage, performance status, and histology. RESULTS Of 193 patients registered, 147 (69 radiotherapy and 78 chemoradiotherapy) were eligible for primary analysis for survival and toxicity. The median progression-free survival (PFS) time was 15 months for eligible patients on the radiotherapy arm and was not reached for the chemo-radiotherapy group. The 3-year PFS rate was 24% versus 69%, respectively (P < .001). The median survival time was 34 months for the radiotherapy group and not reached for the chemo-radiotherapy group, and the 3-year survival rate was 47% versus 78%, respectively (P = .005). One hundred eighty-five patients were included in a secondary analysis for survival. The 3-year survival rate for patients randomized to radiotherapy was 46%, and for the chemoradiotherapy group was 76% (P < .001). CONCLUSION We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival." @default.
- W4385871683 created "2023-08-17" @default.
- W4385871683 creator A5021506059 @default.
- W4385871683 creator A5027009066 @default.
- W4385871683 creator A5034392417 @default.
- W4385871683 creator A5036014755 @default.
- W4385871683 creator A5041539801 @default.
- W4385871683 creator A5042549893 @default.
- W4385871683 creator A5071732749 @default.
- W4385871683 creator A5080425014 @default.
- W4385871683 creator A5085052382 @default.
- W4385871683 creator A5085616547 @default.
- W4385871683 creator A5089737672 @default.
- W4385871683 date "2023-08-20" @default.
- W4385871683 modified "2023-09-24" @default.
- W4385871683 title "Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099." @default.
- W4385871683 doi "https://doi.org/10.1200/jco.22.02764" @default.
- W4385871683 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37586209" @default.
- W4385871683 hasPublicationYear "2023" @default.
- W4385871683 type Work @default.
- W4385871683 citedByCount "0" @default.
- W4385871683 crossrefType "journal-article" @default.
- W4385871683 hasAuthorship W4385871683A5021506059 @default.
- W4385871683 hasAuthorship W4385871683A5027009066 @default.
- W4385871683 hasAuthorship W4385871683A5034392417 @default.
- W4385871683 hasAuthorship W4385871683A5036014755 @default.
- W4385871683 hasAuthorship W4385871683A5041539801 @default.
- W4385871683 hasAuthorship W4385871683A5042549893 @default.
- W4385871683 hasAuthorship W4385871683A5071732749 @default.
- W4385871683 hasAuthorship W4385871683A5080425014 @default.
- W4385871683 hasAuthorship W4385871683A5085052382 @default.
- W4385871683 hasAuthorship W4385871683A5085616547 @default.
- W4385871683 hasAuthorship W4385871683A5089737672 @default.
- W4385871683 hasConcept C126322002 @default.
- W4385871683 hasConcept C141071460 @default.
- W4385871683 hasConcept C143998085 @default.
- W4385871683 hasConcept C168563851 @default.
- W4385871683 hasConcept C2776283816 @default.
- W4385871683 hasConcept C2776694085 @default.
- W4385871683 hasConcept C2778239845 @default.
- W4385871683 hasConcept C2778424827 @default.
- W4385871683 hasConcept C2780456651 @default.
- W4385871683 hasConcept C509974204 @default.
- W4385871683 hasConcept C71924100 @default.
- W4385871683 hasConceptScore W4385871683C126322002 @default.
- W4385871683 hasConceptScore W4385871683C141071460 @default.
- W4385871683 hasConceptScore W4385871683C143998085 @default.
- W4385871683 hasConceptScore W4385871683C168563851 @default.
- W4385871683 hasConceptScore W4385871683C2776283816 @default.
- W4385871683 hasConceptScore W4385871683C2776694085 @default.
- W4385871683 hasConceptScore W4385871683C2778239845 @default.
- W4385871683 hasConceptScore W4385871683C2778424827 @default.
- W4385871683 hasConceptScore W4385871683C2780456651 @default.
- W4385871683 hasConceptScore W4385871683C509974204 @default.
- W4385871683 hasConceptScore W4385871683C71924100 @default.
- W4385871683 hasIssue "24" @default.
- W4385871683 hasLocation W43858716831 @default.
- W4385871683 hasLocation W43858716832 @default.
- W4385871683 hasOpenAccess W4385871683 @default.
- W4385871683 hasPrimaryLocation W43858716831 @default.
- W4385871683 hasRelatedWork W13394025 @default.
- W4385871683 hasRelatedWork W2363409655 @default.
- W4385871683 hasRelatedWork W2394853503 @default.
- W4385871683 hasRelatedWork W2404042595 @default.
- W4385871683 hasRelatedWork W2406263212 @default.
- W4385871683 hasRelatedWork W2408650435 @default.
- W4385871683 hasRelatedWork W2418474598 @default.
- W4385871683 hasRelatedWork W2418663701 @default.
- W4385871683 hasRelatedWork W363598932 @default.
- W4385871683 hasRelatedWork W4308718010 @default.
- W4385871683 hasVolume "41" @default.
- W4385871683 isParatext "false" @default.
- W4385871683 isRetracted "false" @default.
- W4385871683 workType "article" @default.